Journal of the American Academy of Dermatology · 2026
Real-world outcomes of 24-week abrocitinib tapering in moderate-to-severe atopic dermatitis: Feasibility and regimen comparison.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Deng Sisi, He Yuanxiong, Wang Huan, Chen Qiquan, Gao Cuie, Song Zhiqiang
Аннотация
BACKGROUND: Evidence regarding the feasibility of Janus kinase inhibitors tapering following adequate response in moderate-to-severe atopic dermatitis (AD) remains limited, and no head-to-head comparisons of tapering regimens have been conducted.
OBJECTIVE: To evaluate the feasibility of 24-week abrocitinib tapering in moderate-to-severe AD patients having achieved adequate response and compare 2 tapering methods.
METHODS: This retrospective study enrolled moderate-to-severe AD patients who achieved adequate clinical response with abrocitinib and underwent tapering over 24 weeks via dose reduction or interval extension.
RESULTS: A total of 78 patients (36 dose reduction, 42 interval extension) were included, and successful tapering was achieved in 76 (97.4%). Nonrelapse rates were 97.4% and 91.0% at weeks 12 and 24, respectively. At week 24, mean cumulative dose was reduced by 9892 mg (6908 mg vs 16,800 mg standard), with cost savings of ¥ 2899.5 (¥ 2016.7 vs ¥ 4916.2 projected). Patients with extended dosing intervals had significantly higher strategy-switch rates due to disease fluctuation [28.6% (12/42) vs 8.3% (3/36), P = .041].
LIMITATIONS: The single-center retrospective design, small sample size, and relatively short follow-up duration.
CONCLUSION: Twenty-four-week abrocitinib tapering appears feasible in well-responding moderate-to-severe AD patients, reducing treatment burden while preserving efficacy.
OBJECTIVE: To evaluate the feasibility of 24-week abrocitinib tapering in moderate-to-severe AD patients having achieved adequate response and compare 2 tapering methods.
METHODS: This retrospective study enrolled moderate-to-severe AD patients who achieved adequate clinical response with abrocitinib and underwent tapering over 24 weeks via dose reduction or interval extension.
RESULTS: A total of 78 patients (36 dose reduction, 42 interval extension) were included, and successful tapering was achieved in 76 (97.4%). Nonrelapse rates were 97.4% and 91.0% at weeks 12 and 24, respectively. At week 24, mean cumulative dose was reduced by 9892 mg (6908 mg vs 16,800 mg standard), with cost savings of ¥ 2899.5 (¥ 2016.7 vs ¥ 4916.2 projected). Patients with extended dosing intervals had significantly higher strategy-switch rates due to disease fluctuation [28.6% (12/42) vs 8.3% (3/36), P = .041].
LIMITATIONS: The single-center retrospective design, small sample size, and relatively short follow-up duration.
CONCLUSION: Twenty-four-week abrocitinib tapering appears feasible in well-responding moderate-to-severe AD patients, reducing treatment burden while preserving efficacy.